Don't Jump to Spironolactone or Entresto for HFpEF

You'll see patients with heart failure with PRESERVED ejection fraction (HFpEF) on spironolactone or sacubitril/valsartan (Entresto).

That's because FDA will likely expand approval of these meds beyond heart failure with REDUCED ejection fraction (HFrEF) include some HFpEF patients.

Experts predict these labels may specify HFpEF patients with "mildly reduced" EF, such as about 40% to 50%.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals